Last reviewed · How we verify
Jia Shen Tablet
Jia Shen Tablet is a Traditional Chinese Medicine Small molecule drug developed by Tasly Pharmaceutical Group Co., Ltd. It is currently in Phase 2 development.
The mechanism of action has not been publicly disclosed for this traditional Chinese medicine formulation.
The Jia Shen Tablet is a treatment being studied for Heart Failure and Bronchial Asthma in clinical trials. The exact mechanism of action of the Jia Shen Tablet is currently unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Jia Shen Tablet |
|---|---|
| Sponsor | Tasly Pharmaceutical Group Co., Ltd |
| Drug class | Traditional Chinese Medicine |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure (PHASE2)
- Pharmacokinetic and Pharmacodynamic of Jia Shen Tablets in Chronic Heart Failure (PHASE1)
- Study on the Treatment of Bronchial Asthma With Traditional Chinese Medicine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Jia Shen Tablet CI brief — competitive landscape report
- Jia Shen Tablet updates RSS · CI watch RSS
- Tasly Pharmaceutical Group Co., Ltd portfolio CI
Frequently asked questions about Jia Shen Tablet
What is Jia Shen Tablet?
How does Jia Shen Tablet work?
Who makes Jia Shen Tablet?
What drug class is Jia Shen Tablet in?
What development phase is Jia Shen Tablet in?
Related
- Drug class: All Traditional Chinese Medicine drugs
- Manufacturer: Tasly Pharmaceutical Group Co., Ltd — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing